Results 111 to 120 of about 81,803 (228)

Targeting of BCR-ABL: Lessons learned from BCR-ABL inhibition

, 2016
In 1960 researchers reported that balanced translocation between chromosomes 22 and 9 resulted in the generation of Philadelphia chromosome. This breakthrough revolutionized our knowledge related to leukemia biology and contemporary studies revealed that
de Carlos Back, L. K., Lin, X., Farooqi, A. A., Khalid, S., Aslam, A., Tahir, F., Ismail, M., Qureshi, M. Z., Yaqub, A., Yaylim, I., Attar, R.   +10 more
core   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Role of STAT3 in transformation and drug resistance in CML

Frontiers in Oncology, 2012
Chronic Myeloid Leukemia (CML) is initially driven by the bcr-abl fusion oncoprotein. The identification of bcr-abl led to the discovery and rapid translation into the clinic of bcr-abl kinase inhibitors.
Rajesh R Nair, Joel H Tolentino, Lori A Hazlehurst   +2 more
doaj   +1 more source

Differential in vivo tyrosine kinase inhibitor sensitivities of pediatric ABL‐class Ph‐like B‐acute lymphoblastic leukemia

HemaSphere, Volume 10, Issue 9, September 2026.
Ritul Sharma, Jackson K. Dardis, Huong Anh Mai, Camilo Arenas Merizalde, Cesca van de Ven, Diego A. Bárcenas López, Shubhmita Bhatnagar, Andishe Attarbaschi, Judith M. Boer, Monique L. den Boer, Sarah K. Tasian   +10 more
wiley   +1 more source

Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.

PLoS ONE, 2015
Notch signalling is critical for haemopoietic stem cell (HSC) self-renewal and survival. The role of Notch signalling has been reported recently in chronic myeloid leukaemia (CML) - a stem cell disease characterized by BCR-ABL tyrosine kinase activation.
Abdullah Aljedai, Anne-Marie Buckle, Prashant Hiwarkar, Farhatullah Syed   +3 more
doaj   +1 more source

Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

, 2008
Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265), Arghya Ray (203488), Andrew L. Kung (9710962), Renee D. Wright (15042080), Richard Stone (86371), Ellen Weisberg (203474), Rosemary Barrett (203507), James D. Griffin (203544), Sophia Adamia (203502), Douglas W. McMillin (348456), Constantine Mitsiades (381062)   +10 more
core   +1 more source

Targeting HSPA8 to repress GPX4 and induce ferroptosis in BCR-ABL positive leukemia

Biomedical Technology
BCR-ABL positive (BCR-ABL+) leukemia is driven by constitutive activation of tyrosine kinase activity, with tyrosine kinase inhibitors (TKIs) serving as the standard treatment. However, resistance to TKIs remains a significant clinical challenge. In this
Shuxin Zhong, Dingrui Nie, Xueting Peng, Kangjie Qiu, Jinyi Liu, Zhangshuai Dai, Xianfeng Zha, Songnan Sui, Weini Li, Weizhang Wang, Cunte Chen, Yangqiu Li, Chengwu Zeng   +12 more
doaj   +1 more source

Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

, 2008
Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265), Arghya Ray (203488), Andrew L. Kung (9710962), Renee D. Wright (15042080), Richard Stone (86371), Ellen Weisberg (203474), Rosemary Barrett (203507), James D. Griffin (203544), Sophia Adamia (203502), Douglas W. McMillin (348456), Constantine Mitsiades (381062)   +10 more
core   +1 more source

Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

, 2008
Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265), Arghya Ray (203488), Andrew L. Kung (9710962), Renee D. Wright (15042080), Richard Stone (86371), Ellen Weisberg (203474), Rosemary Barrett (203507), James D. Griffin (203544), Sophia Adamia (203502), Douglas W. McMillin (348456), Constantine Mitsiades (381062)   +10 more
core   +1 more source

Bcr: A conditional inhibitor of Bcr-Abl oncoprotein

, 1999
Chronic myelogenous leukemia (CML) is characterized cytogenetically by the presence of the Philadelphia chromosome and clinically by the clonal expansion of the hematopoietic stem cells and the accumulation of large numbers of myeloid cells. Philadelphia
Wu, Yun
core   +1 more source